- Second quarter total revenue of $23.2 million
- Positive cash flows from operations, with Adjusted EBITDA(1) of $1.7 million
- Investor webinar scheduled for Thursday, August 13, 2026 at 11:00 AM ET / 8:00 AM PT
TORONTO, ONTARIO, August 13, 2026 – NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”) operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain-related medical services, today announced its financial and operating results for the three and six months ended June 30, 2026 and information regarding the Company’s investor webinar on Thursday, August 13, 2026. All figures are in Canadian dollars, unless otherwise noted.
“Our business continued to perform well in the quarter. Excluding the one-time material payment that positively impacted revenues and Adjusted EBITDA in the prior year period, we recorded good organic revenue growth driven by record patient visits,” said Stephen Lemieux, NeuPath’s Chief Executive Officer. “We are focused on our growth strategy to drive shareholder value. We welcomed six new physicians to NeuPath subsequent to the quarter, which will expand our service offering for patients in our existing facilities.”
Financial and Operational Highlights
In the comparative quarter, the Company received a $1.9 million material one-time payment that had a positive impact on revenue and a $0.6 million positive impact on Adjusted EBITDA (the “Prior Year Payment”). The Prior Year Payment was related to positive adjustments to physician reimbursement rates for prior periods. Excluding the impact of the Prior Year Payment in the comparative quarter, revenue for the three and six-month periods ended June 30, 2025 was $21.7 million and $41.1 million and Adjusted EBITDA was $1.7 million and $2.9 million, respectively.
Including the impact of the Prior Year Payment in the comparative periods as reported:
- Total revenue was $23.2 million and $44.7 million for the three and six months ended June 30, 2026, down 2% compared to the comparative quarter and up 4% year-over-year;
- Adjusted EBITDA was $1.7 million and $3.2 million for the three and six months ended June 30, 2026, down 23% compared to the comparative quarter and 10% year-over-year; and
- As at June 30, 2026, the Company had $3.5 million in cash and cash equivalents and interest-bearing long-term debt of $5.9 million.
- IFRS Accounting Standards (“IFRS”) and Other Financial Measures defined by the Company below.
View entire press release – PDF